IFRX · InflaRx N.V.

InflaRx N.V. reported positive mechanistic data for its lead candidate, izicopan, an oral C5a receptor inhibitor. The announcement detailed results from a Ki-based time-dependent inhibition (TDI) study designed to provide a definitive assessment of potential drug-drug interaction risks. The study confirmed that izicopan does not inhibit the CYP3A4 enzyme (IC₅₀ > 100 µM) and showed no time-dependent inhibition up to the highest tested concentration. This is a significant differentiator compared to the marketed C5aR inhibitor, which has been shown to inhibit CYP3A4. The absence of CYP3A4 inhibition suggests a lower risk for drug-drug interactions and liver toxicity, which is particularly relevant for patient populations requiring concomitant medications such as corticosteroids. These findings complement previously reported clinical data showing izicopan was well-tolerated with a favorable PK/PD profile and biologic-like efficacy in Phase 2a trials for hidradenitis suppurativa and chronic spontaneous urticaria.